BioNTech Results Presentation Deck

BNT113: Potent Antigen-Specific T Cell Responses in Phase 1 Trial 1,2 A Overview of T cell responses Arm 1A ● ● ● 28 CD4+ and CD8+ T cell responses Responses detectable ex vivo, implying high numbers of T cells Responses against multiple E6 or E7 epitopes BO Arm 1A, adjuvantx Antigen E6 E7 Patient 1 18 Pre vaccination b1 b5 CD8 CD8 CD4 CD8 CD4 17 d5 Patient 2 TNTC Cohort 1 TD 29 μg 16 Patient 3 ELISPOTS³ Patient 7 CD8 response to vaccine targets Post vaccination b6 b1 309 c1 504 NR NR NR NR NR NR CD8 NR NE NR NR 65 Patient 4 3 d5 f5 TNTC b2 303 445 Patient 5 b6 d6 f6 Patient 6 CD4/ CD4/ CD8 CD8 TD, total dose; CD, Cluster of Differentiation; NE, Not Evaluated; NR, Not Reported; PBMC, peripheral blood mononuclear cells ¹HARE-40 trial Patient 7 Pepmix E6 Pepmix E7 PBMCs only Cohort 2 TD 78.2 μg PBMCs only Anti-CD3 Patient 8 CD4 Bulk CD8 Patient 9 b1 b5 Patient 10 TNTC Patient 11 b2 NR b6 01 Pre vaccination 39 b5 Number of patients 727 Arm 1A patients 15 b2 10 b6 LO O E6 E7 Positive response No response Not evaluable ELISPOTS³ Patient 6 CD4 response to vaccine targets Post vaccination b1 10 b5 b2 b6 Type of response to E6 2Presented at CIMT 2019; BNT113 is currently being studied in an investigator-initiated Phase 1 trial. ³ELISPOT (Enzyme Linked Immuno Spot Assay) data of selected patients. Data were generated using IFN-y ELISPOT directly ex-vivo with overlapping peptides covering the whole length of vaccine antigens (PepMix). b1 399 b5 22% 889 45% ☐CD4 response CD8 response ☐CD4/CD8 response b2 426 33% b6 D Pepmix E6 PBMCs only PBMCs only Anti-CD3 BIONTECH

View entire presentation